PTGS2 and familial pancreatic carcinoma: In one clinical study, 25 patients, aged 43–77 years old, were needed to consider the biological activity and safety of curcumin in pancreatic cancer patients by oral administration with 8 g of curcumin capsules, the down-regulation of NF-κB and COX-2 suggested curcumin was effective enough in pancreatic cancer [55].